Darrin D. Stuart

3.8k total citations · 1 hit paper
50 papers, 2.3k citations indexed

About

Darrin D. Stuart is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Darrin D. Stuart has authored 50 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 18 papers in Oncology and 13 papers in Computational Theory and Mathematics. Recurrent topics in Darrin D. Stuart's work include Melanoma and MAPK Pathways (26 papers), Computational Drug Discovery Methods (13 papers) and HER2/EGFR in Cancer Research (8 papers). Darrin D. Stuart is often cited by papers focused on Melanoma and MAPK Pathways (26 papers), Computational Drug Discovery Methods (13 papers) and HER2/EGFR in Cancer Research (8 papers). Darrin D. Stuart collaborates with scholars based in United States, Switzerland and Canada. Darrin D. Stuart's co-authors include Meghna Das Thakur, Theresa M. Allen, William R. Sellers, Nancy Pryer, Reinhard Dummer, Fernando Salangsang, Allison Landman, Martin McMahon, Mitchell P. Levesque and Matthew Holderfield and has published in prestigious journals such as Nature, JNCI Journal of the National Cancer Institute and Cancer Cell.

In The Last Decade

Darrin D. Stuart

48 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

2013 539 citations Meghna Das Thakur, Fernando Salangsang et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darrin D. Stuart United States	25	1.7k	819	267	241	230	50	2.3k
John G. Moffat United States	20	1.9k 1.1×	809 1.0×	461 1.7×	266 1.1×	250 1.1×	37	2.8k
Maria Karasarides United States	12	1.8k 1.0×	833 1.0×	237 0.9×	253 1.0×	262 1.1×	20	2.3k
Paul Wan United Kingdom	9	1.9k 1.1×	991 1.2×	326 1.2×	228 0.9×	425 1.8×	9	2.5k
Alastair J. King United States	18	1.6k 0.9×	659 0.8×	195 0.7×	149 0.6×	182 0.8×	28	2.0k
Jingsong Yang United States	21	1.4k 0.8×	898 1.1×	167 0.6×	137 0.6×	211 0.9×	37	2.1k
Inna V. Fedorenko United States	16	1.3k 0.8×	809 1.0×	238 0.9×	120 0.5×	190 0.8×	27	1.6k
Kim H.T. Paraiso United States	23	1.9k 1.1×	954 1.2×	251 0.9×	368 1.5×	203 0.9×	28	2.5k
Ayana Sawai United States	9	2.7k 1.6×	1.1k 1.4×	276 1.0×	335 1.4×	354 1.5×	10	3.3k
Jennifer L. Stamos United States	14	2.2k 1.3×	788 1.0×	194 0.7×	210 0.9×	195 0.8×	17	3.3k

Countries citing papers authored by Darrin D. Stuart

Since Specialization

Citations

This map shows the geographic impact of Darrin D. Stuart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darrin D. Stuart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darrin D. Stuart more than expected).

Fields of papers citing papers by Darrin D. Stuart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darrin D. Stuart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darrin D. Stuart. The network helps show where Darrin D. Stuart may publish in the future.

Co-authorship network of co-authors of Darrin D. Stuart

This figure shows the co-authorship network connecting the top 25 collaborators of Darrin D. Stuart. A scholar is included among the top collaborators of Darrin D. Stuart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darrin D. Stuart. Darrin D. Stuart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jean, David J. St., Brendon Ladd, Brendan J. Hilbert, et al.. (2023). STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts. Cancer Discovery. 13(11). 2432–2447. 41 indexed citations

Stuart, Darrin D., et al.. (2023). Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science. Cancer Discovery. 13(10). 2131–2149. 9 indexed citations

Crowe, Matthew S., Tatiana Zavorotinskaya, Charles F. Voliva, et al.. (2021). RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation. Molecular Cancer Research. 19(6). 1063–1075. 3 indexed citations

Feng, Tianshu, Javad Golji, Ailing Li, et al.. (2019). Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAF V600-Mutant Melanoma Patient-Derived Xenografts. Molecular Cancer Therapeutics. 18(12). 2421–2432. 2 indexed citations

Feng, Tianshu, Frederic Sigoillot, Felipe C. Geyer, et al.. (2018). Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. Molecular Cancer Research. 17(1). 199–211. 49 indexed citations

Gao, Yijun, Matthew T. Chang, Daniel J. McKay, et al.. (2018). Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery. 8(5). 648–661. 87 indexed citations

Smith, Aaron, Zhi‐Jie Ni, Daniel Poon, et al.. (2017). Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(23). 5221–5224. 8 indexed citations

Holderfield, Matthew, Edward Lorenzana, Ben Weisburd, et al.. (2014). Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research. 74(8). 2238–2245. 20 indexed citations

Paraiso, Kim H.T., Meghna Das Thakur, Bin Fang, et al.. (2014). Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype. Cancer Discovery. 5(3). 264–273. 85 indexed citations

10.

Chen, Guo, Nitin Chakravarti, Kimberly Aardalen, et al.. (2014). Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clinical Cancer Research. 20(21). 5537–5546. 120 indexed citations

11.

Thakur, Meghna Das, Fernando Salangsang, Allison Landman, et al.. (2013). Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494(7436). 251–255. 539 indexed citations breakdown →

12.

Menezes, Daniel L., Pietro Taverna, Michael Rugaard Jensen, et al.. (2012). The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo. Molecular Cancer Therapeutics. 11(3). 730–739. 57 indexed citations

13.

Su, Yingjun, Anna E. Vilgelm, Mark C. Kelley, et al.. (2012). RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research. 18(8). 2184–2198. 47 indexed citations

14.

Tseng, Jeffrey R., et al.. (2011). Use of DNA Microarray and Small Animal Positron Emission Tomography in Preclinical Drug Evaluation of RAF265, a Novel B-Raf/VEGFR-2 Inhibitor. Neoplasia. 13(3). 266–IN17. 24 indexed citations

15.

Stuart, Darrin D. & William R. Sellers. (2009). Linking somatic genetic alterations in cancer to therapeutics. Current Opinion in Cell Biology. 21(2). 304–310. 48 indexed citations

16.

Amiri, Payman, Mina Aikawa, Darrin D. Stuart, et al.. (2006). CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. Cancer Research. 66. 1140–1140. 18 indexed citations

17.

Venetsanakos, Eleni, Darrin D. Stuart, Nguyêñ Duy Tân, et al.. (2006). CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models. Cancer Research. 66. 1140–1140. 10 indexed citations

18.

Stuart, Darrin D., Sean C. Semple, & Theresa M. Allen. (2004). High Efficiency Entrapment of Antisense Oligonucleotides in Liposomes. Methods in enzymology on CD-ROM/Methods in enzymology. 387. 171–188. 17 indexed citations

19.

Stuart, Darrin D., Anthony P. Cullen, J. G. Sivak, & Michael J. Doughty. (1994). Optical effects of UV-A and UV-B radiation on the cultured bovine lens. Current Eye Research. 13(5). 371–376. 29 indexed citations

20.

Cowey, Colin B., C. Young Cho, J. G. Sivak, J. Weerheim, & Darrin D. Stuart. (1992). Methionine Intake in Rainbow Trout (Oncorhynchus mykiss), Relationship to Cataract Formation and the Metabolism of Methionine. Journal of Nutrition. 122(5). 1154–1163. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact